StarryGene Biotech Secures Tens of Millions of RMB in Series A2 Funding to Advance Ophthalmic Gene Therapy Pipeline

Investment Circle (ID: pedaily2012) September 12th, News,StarryGene（StarryGene) CompletedTens of Millions of RMBA2RoundFinancing, this round of financing was led byCoWin Ventures、CASVCand others jointly completed. The funds from this round of financing will provide important financial support for StarryGene's product development, with a focus on advancing the company's core products.—— wAMDProductXMVA09TheⅡPhase clinical trials, as well as simultaneous promotiondAMD Pipeline andTEDPipeline's pharmaceutical, preclinical research andIITClinical Trial.

StarryGene was founded in2019Year8Month, a high-tech enterprise based on cutting-edge gene editing technology for the development of ophthalmic disease gene therapy products, focusing on the development of ophthalmic gene therapy drugs. The core team of StarryGene is...“Jie Qing”Led by a doctoral entrepreneurial team, which has two core technology platforms in the R&D sector,AAV-Antibody Gene Drug Platform (Dual-Antibody Optimization Platform, Capsid Screening Platform) and Gene Editing Platform.

For this round of financing, Xiaoming Liu, the co-founder of StarryGene,CEODr. Cai Yuan said:From the bottom of my heart, I sincerely thank all the investors for their long-term support and trust. As an entrepreneur without industry experience, I deeply cherish the invaluable support from all investors for StarryGene. This trust is something I hold in high regard. With the efficient cooperation of the team, our core product...XMVA09Injection Solution with ExcellentIPhase I clinical safety and efficacy data, successfully advancing to Phase II clinical research, becoming the world's first to enter the second phase of clinical trials.AAVDual-target, also the first new capsid gene therapy project in ophthalmology in China to enter Phase II clinical trials. In the future, StarryGene will continue to accelerate the advancement of its pipeline, committing to provide more innovative and efficient gene therapy drugs for patients with ophthalmic diseases. Meanwhile, as StarryGene enters a new phase, the continuous support and assistance from senior industry experts, friends, and partners remain crucial.